Human Metabolome Technologies, Inc. (6090.T)
Tokyo · JPY · Healthcare · Diagnostics & Research
¥592 (+0.85%) as of
Key statistics
- Market cap
- 3.18B
- P/E (TTM)
- 16.78
- Forward P/E
- 17.46
- EPS (TTM)
- 35.27
- Dividend yield
- 3.07%
- 52-week range
- 570.00 – 766.00
- Beta
- -0.05
- Revenue (TTM)
- 1.42B
- Profit margin
- 14.07%
- Volume
- 4.90k
About Human Metabolome Technologies, Inc.
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted panels, flux analysis, and lipidomics services. The company offers solutions for cancer metabolism; metabolic flux analysis; functional food; neurobiology research; renal and disease markers; skin and dermo-metabolomics; T-cell and B-cell metabolism; bacterial, fungal, and algae metabolism; tastant profiling; biomarker discovery, mitochondrial metabolism; patient profiling and subtyping; cellular engineering; and biomanufacturing and metabolomics applications. Human Metabolome Technologies, Inc. has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Headquarters
- Tsuruoka, Japan
- Employees
- 65
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.